Endpoints News 生物医药· Ayisha Sharma·· 2026-10-15AI 评分44
Vanda 社交焦虑症药物 VQW-765 三期试验在女性患者中失败
Vanda’s social anxiety drug flunks Phase 3 trial in female patients
AI 导读
Vanda Pharmaceuticals 宣布,由于一项晚期试验在女性患者中未达终点,暂停其社交焦虑症药物 VQW-765 的研发项目。
正文
Vanda Pharmaceuticals said Wednesday it is putting its social anxiety disorder program on hold following a late-stage trial failure.
The biotech’s drug, called VQW-765,
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news